ArticleOrphanet journal of rare diseases2026
Clinical characteristics and a screening tool for VEXAS syndrome: a case-control study from China.
Article in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundVEXAS syndrome is a severe autoinflammatory disease characterized by systemic inflammation, rheumatic manifestations, and hematologic abnormalities. Its clinical heterogeneity and overlap with other conditions complicate diagnosis. No case series have been reported from China. This study aimed to (1) describe the clinical features of Chinese patients with VEXAS syndrome and (2) propose screening recommendations to facilitate earlier identification.
methodsWe conducted a retrospective cohort study at Peking Union Medical College Hospital, enrolling 57 male patients with unexplained systemic inflammation and hematologic abnormalities. UBA1 gene sequencing was performed using bone marrow or peripheral blood samples. Clinical and laboratory data were extracted from electronic medical records. A screening model was developed using LASSO regression based on core features of confirmed cases and externally validated in two independent cohorts undergoing UBA1 sequencing.
resultsAmong 57 suspected cases, 21 carried pathogenic UBA1 variants. Compared with non-VEXAS patients, VEXAS patients more frequently showed older age at onset, skin lesions, chondritis, macrocytic anemia, and characteristic bone marrow vacuolization. Importantly, skin lesions were the initial presenting symptom in over half of VEXAS patients, whereas fever predominated in the non-VEXAS group. Rare manifestations included glomerulonephritis, acute cerebral infarction, and pulmonary arterial involvement. A novel UBA1 variant (p.Thr318Met) was also identified. A screening model incorporating age at onset, skin lesions, chondritis, macrocytic anemia, and bone marrow vacuoles demonstrated good sensitivity and specificity in an external validation cohort.
conclusionThis study is the first to characterize the clinical features of VEXAS syndrome in a Chinese population and to delineate its phenotypic spectrum. The proposed screening tool provides a practical aid for clinicians in identifying suspected cases and may facilitate improved diagnostic pathways and patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.